Allegro DVT and Beamr Announce the World’s First Content-Adaptive Silicon IP Video Encoder
23.9.2021 16:35:00 EEST | Business Wire | Press release
Allegro DVT, the leading provider of video processing silicon IPs, and Beamr, the leading developer of content-adaptive video encoding technologies, today announced an integrated solution that combines Beamr’s CABR silicon IP with Allegro’s video encoding IP to create the world’s first content-adaptive silicon IP encoder. Using the integrated solution, ASIC vendors can now create high-performance, low latency video encoding chips that significantly reduce video bitrate without compromising quality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005015/en/
(Photo: Allegro DVT)
Allegro DVT’s E2xx family of silicon proven IPs is a highly optimized video encoding solution targeted at ASIC implementations in a wide range of process node technologies down to 3nm. It provides support for mainstream image and video formats including JPEG, H.264, HEVC, VP9 and AV1, at up to 8K resolutions.
Beamr’s patented, Emmy® award-winning CABR engine enables reducing the bitrate of video streams encoded by any standard video encoder, including the latest AV1 codec, by up to 50% without compromising perceptual quality. The reduced-bitrate streams remain fully standards-compliant, and can be decoded by any standard video decoder.
“For the past decade, Beamr’s CABR software solutions have enabled optimized video compression for our customers, resulting in an improved viewing experience, reduced network congestion, and lower TCO”, said Sharon Carmel, Founder & CEO of Beamr. “When developing our silicon IP implementation, we’ve found Allegro’s video encoders to be the perfect partner for integration, due to their superior video quality, high performance, and support for the latest video codecs. By integrating our CABR Silicon IP library with Allegro’s video encoders, we are now bringing the optimization benefits to ASIC providers, who can utilize them in all video applications from video surveillance and IoT to 8K live broadcasting, low latency cloud gaming and more.”
Nouar Hamze, Allegro DVT’s CEO commented: “The dramatic increase of video usage is forcing the industry to consider HW based video encoding solutions to control implementation complexity and cost. The integrated Allegro DVT E2xx/Beamr CABR solution provides our common customer base with the most advanced ASIC-ready option to further improve video compression efficiency. The combined solution is immediately available for evaluation through a bit-accurate software simulation model.”
About Beamr
https://beamr.com/
About Allegro DVT
http://www.allegrodvt.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005015/en/
Contact information
Nathalie Brault
marcom@allegrodvt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fastly Joins DIMPACT to Collaborate on Digital Sustainability8.7.2026 15:00:00 EEST | Press release
Fastly, Inc. (NASDAQ: FSLY), a leading global edge cloud platform, today announced it has become a participant of DIMPACT, the coalition of leading organizations working to align industry changemakers and policymakers around meaningful, science-based solutions that reduce the environmental impacts of serving digital media products. As the first edge cloud platform provider to join the coalition, Fastly brings critical, real-world edge network data and infrastructure expertise and a transparent approach to emissions calculation and reporting to help major media, streaming, and publishing companies understand and optimize their digital carbon footprints. “We’re thrilled to welcome Fastly to the DIMPACT initiative. Their participation strengthens DIMPACT's ability to advance a more accurate, data-driven approach to measuring and reducing digital emissions,” said Jason Bell, Director at SLR Consulting and Executive Sponsor of DIMPACT. “Accurately calculating digital emissions requires a de
PubNub Introduces Blocks.ai: The Control Plane and Network Layer For AI Agents8.7.2026 15:00:00 EEST | Press release
PubNub introduces Blocks.ai today, a global network to connect and control agents across all agent frameworks, providers, and APIs. Blocks.ai lets developers reach their existing AI agents regardless of where they are hosted. Blocks Network supports all AI agent use cases without opening inbound ports, setting up tunnels, changing DNS, or modifying firewall rules. For more than a decade, PubNub has been the infrastructure and platform for real-time connectivity supporting billions of devices, now, PubNub delivers Blocks Network connecting the Internet of Agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708521206/en/ AI agents have become increasingly critical to businesses who want control over their models, code, and data. But once those agents are running locally or behind a firewall, making them reachable from custom frontends can require brittle infrastructure work. This is a key reason why McKinsey estimates th
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development8.7.2026 15:00:00 EEST | Press release
STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to expand access to high-quality human induced pluripotent stem cell (iPSC) starting materials, giving cell therapy developers worldwide a faster, lower-risk path from research to the clinic. Under the agreement, STEMCELL will manufacture and distribute research-use-only (RUO) iPSC lines derived directly from LineaBio's Good Manufacturing Practices (GMP) iPSC lines, and will offer the matched GMP lines to developers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708212795/en/ Partnership pairs GMP-manufactured iPSC lines with matched RUO equivalents, giving developers well-characterized, donor-eligible starting materials from early research through clinical development. Supporting comparability data for the RUO and GMP lines to be presented at the 2026 ISSCR Annual Meeting in Montréal, Canada
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 15:00:00 EEST | Press release
The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer of its kind, combining quantum error correction with NISQ qubits. The system will be delivered in 2027, followed by a series of upgrades delivered in multiple phases with an increasing number of logical qubits. The IQM Halocene H4 and the upgraded systems will enable LUMI consortium users, for the first time, to develop and implement Quantum Error Correction (QEC) concepts on a world-leadi
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden, the lack of targeted treatment makes the disease hard to control,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “This Breakthrough Therapy designation demonstrates that enpatoran has the potential to redefine how we approach lupus, by addressing the visible burden of rash, while potentially driving benefit beyond the skin. We look forward to working with the FDA to potentially bring this much-needed option to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom